This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.

EAT-PK

  • Research type

    Research Study

  • Full title

    Does Extra-Corporeal Membrane Oxygenation alter anti-infectives therapy pharmacokinetics in adult critically ill patients?\n\n

  • IRAS ID

    228196

  • Contact name

    Anna Reed

  • Contact email

    a.reed@rbht.nhs.uk

  • Sponsor organisation

    Royal Brompton and Harefield NHS Foundation Trust

  • Duration of Study in the UK

    4 years, 0 months, 1 days

  • Research summary

    Extracorporeal membrane oxygenation (ECMO) is a term used to describe a circuit outside the body (“extracorporeal“) that directly oxygenates and removes carbon dioxide from the blood acting as an advanced life support system. This can be used to support patients with life threatening respiratory or cardiac failure until they can have a heart or lung transplant. Being on ECMO may affect the way the body handle medicines. Antibacterial and antifungal medicines are often used to treat infection while patients are on ECMO and in the intensive care unit. Changes in these may lead to either failure to treat the infection or undesirable drug side-effects. The aim of this study is to understand how ECMO affects these medicines and provide guidance to improve dosing and hence outcome in these patients.

  • REC name

    London - South East Research Ethics Committee

  • REC reference

    18/LO/0691

  • Date of REC Opinion

    25 May 2018

  • REC opinion

    Favourable Opinion